UR Advanced Therapeutics (URAT), the Hyderabad-based biotechnology firm behind BioVaram brand, and Japanese company Teijin have signed an agreement to leverage each company’s strengths to deliver solutions across both countries.Specifically, the agreement is to explore opportunities for expanding usage of Teijin Group’s implantable medical devices and regenerative medicine products in India as well as introducing BioVaram’s product portfolio into the Japanese market.Teijin and URAT will explore regulatory approval and commercialisation of Teijin Medical Technologies cardiovascular repair patch Synfolium in India; and opportunities for expanding use of Japan Tissue Engineering Co’s regenerative medicine products in India. They will work for development and commercialisation of BioVaram technologies in Japan, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.“By combining the expertise of both companies, we are confident in our ability to deliver innovative therapies that address unmet medical needs in both countries,” said Takayuki Nakano, mission executive and general manager-Regenerative Medicine and Implantable Medical Device Division of Teijin.URAT founder and CEO Jaganmohan Reddy said the “partnership strengthens our capabilities in research, innovation and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram’s products to global markets.”The two companies will assess business feasibility, regulatory pathways, technical integration and market needs to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy and pursue plans for introducing Synfolium in India, the companies said in a release on Thursday (November 13, 2025).Published - November 14, 2025 01:27 pm IST